Praetorian Bio is proud to announce its participation in the World Vaccine Congress Europe 2025, where the company will present its preclinical data for the first time. Alongside its startup booth, the team will share a scientific poster featuring exciting proof-of-concept results from its oral vaccine program .
The data demonstrate clear preclinical proof-of-concept for an intranasal vaccine designed to prevent dental caries. In animal studies, vaccination induced strong systemic IgG and IgA responses against Streptococcus mutans and, importantly, mucosal IgA at the site of infection. Antibodies also recognized S. sobrinus, showing cross-reactivity and broad protection against the two major bacterial drivers of cavities. These results mark the first demonstration that a mucosal vaccine can generate broad protective immunity against dental caries .
“These results are a major milestone for Praetorian Bio,” said Dr. Dinja Oosterhoff, Chief Scientific Officer of the Company. “We now have compelling preclinical evidence that mucosal vaccines can protect against cavities, one of the most prevalent diseases in the world. Sharing this breakthrough at WVC allows us to engage with the global vaccine community and build the collaborations that will carry us into the clinic.”
With this preclinical milestone achieved, Praetorian Bio is now focused on advancing the program toward first-in-human studies, reinforcing its mission to transform oral health through prevention for billions of people worldwide.
